Milecular diagnosis of EGFR gene mutations for biological therapy with tyrosine kinase inhibitors in patients with non-small-cell ung cancer.

Abstract

Another possible extension of the existing treatment in patients with NSCLC and in extending their lives is now available to biological treatment with inhibitors of EGFR tyrosine kinase domain. The condition, however, is good and fast diagnosis of activating mutations in the gene for this receptor.

Article summary describes the methods available today, relating to the mutational analysis of EGFR gene

Keywords

• NSCLC
• biological therapy
• trediction
• EGFR
• tyrosine kunase inhibitors
• mutation
• analysis